Conversely, we continued to offer surgical treatment with curative intent to patients with suspected aggressive PCa and localized renal cell carcinoma (RCC), as evidenced by the higher median prostate-specific antigen (PSA) levels among PCa patients during the COVID-19 period [10 (6–14) vs. 7 (5–13) ng/mL]. This evidence concerns the gene KLK3 and renal cell carcinoma.